drug
mivocabtagene autoleucel
Phase 3updated 6mo agoby $KYTX Kyverna Therapeutics, Inc.
Phase 3community read0 votes
all catalysts(0)
nothing on the calendar yet
News(10)
- Kyverna abandons next-gen autoimmune CAR-T once touted as follow-up to miv-celKyverna is halting work on a next-gen CD19 CAR-T therapy as the biotech seeks FDA approval for what could become the first CAR-T treatment for an autoimmune disease.fiercebiotech · 7d ago
- Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune pushSail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.biospace · 17d ago
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…biospace · 1mo ago
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…biospace · 1mo ago
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a rollSummit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene t…biospace · 1mo ago
- Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability dataKyverna Therapeutics' miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff person syndrome, further derisking an upcoming FDA application, William Blai…biospace · 1mo ago
- Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snagsAs two Big Pharma players in the autoimmune CAR-T space face unexpected safety setbacks, Kyverna Therapeutics is reporting long-term clinical data that showcase sustained efficacy alongside an unbl…fiercebiotech · 1mo ago
- Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study haltsWall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.biopharma_dive · 2mo ago
- Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapyElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.biospace · 3mo ago
- Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesRoche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…fiercebiotech · 3mo ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that